Table 4. The prognostic value of NLRs and NLRcs at different time points for overall survival in 195 hepatocellular carcinoma patients by multivariate analyses.
| Variables | (1) OS | (2) OS | (3) OS | (4) OS | (5) OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||||
| Tumor Diameter | 1.292 (0.535, 3.116) | 0.569 | 1.400 (0.594, 3.300) | 0.442 | 2.044 (0.859, 4.862) | 0.106 | 1.557 (0.643, 3.773) | 0.327 | 1.565 (0.647, 3.787) | 0.320 | ||||
| Vascular invasion | 3.074 (0.400, 23.613) | 0.280 | 2.684 (0.349, 20.645) | 0.343 | 3.109 (0.411,23.502) | 0.272 | 3.406 (0.449, 25.842) | 0.236 | 4.070 (0.534, 31.040) | 0.176 | ||||
| BCLC stage | 0.565 (0.070, 4.545) | 0.591 | 0.546 (0.068, 4.371) | 0.569 | 0.398 (0.050, 3.190) | 0.386 | 0.466 (0.057, 3.835) | 0.478 | 0.399 (0.049, 3.279) | 0.393 | ||||
| AFP | 2.137 (0.994, 4.594) | 0.052 | 2.289 (1.068, 4.905) | 0.033 | 2.493 (1.139, 5.456) | 0.022 | 2.027 (0.957, 4.296) | 0.065 | 2.304 (1.064, 4.986) | 0.034 | ||||
| HBV-DNA | 2.239 (0.998, 5.023) | 0.051 | 2.102 (0.925, 4.775) | 0.076 | 2.075 (0.920, 4.684) | 0.079 | 2.164 (0.962, 4.872) | 0.062 | 2.246 (1.001, 5.041) | 0.050 | ||||
| Pre-NLR | 1.508 (0.715, 3.182) | 0.281 | ||||||||||||
| NLR (4–8 w) | 2.601 (1.230, 5.502) | 0.012 | ||||||||||||
| NLR (3–6 m) | 3.939 (1.807, 8.583) | 0.001 | ||||||||||||
| NLRc (4–8 w) | 0.173 | |||||||||||||
| NLRc (4–8 w) ≥25% decrease | 0.899 (0.385, 2.101) | 0.806 | ||||||||||||
| NLRc (4–8 w) ≥25% increase | 2.162 (0.777, 6.013) | 0.140 | ||||||||||||
| NLRc (3–6 m) | 0.073 | |||||||||||||
| NLRc (3–6 m) ≥25% decrease | 0.632 (0.258, 1.544) | 0.314 | ||||||||||||
| NLRc (3–6 m) ≥25% increase | 1.978 (0.806, 4.856) | 0.136 | ||||||||||||
BCLC, Barcelona clinic liver cancer; AFP, α-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; Pre-NLR, preoperative NLR; NLRc, changes of NLR.